

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT
NATURE OF CONVEYANCE:		Assignment of Undivided Interest
CONVEYING PARTY DATA		
Name		Execution Date
AMGEN INC.		05/30/2007
RECEIVING PARTY DATA		
Name:	MEDAREX, INC.	
Street Address:	707 State Road, Suite 206	
City:	Princeton	
State/Country:	NEW JERSEY	
Postal Code:	08540	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	10684957	
CORRESPONDENCE DATA		
Fax Number:	(206)233-0644	
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	206-265-7000	
Email:	lindhold@amgen.com	
Correspondent Name:	DeDe Lindholm	
Address Line 1:	1201 Amgen Ct. West	
Address Line 4:	Seattle, WASHINGTON 98119-3105	
ATTORNEY DOCKET NUMBER:	A-838-US-NP	
NAME OF SUBMITTER:	Rosemary Sweeney	
Total Attachments: 2		
source=Amgen-Medarex US10684957#page1.tif		
source=Amgen-Medarex US10684957#page2.tif		

CH \$40.00 10684957

ASSIGNMENT


Whereas, AMGEN INC., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320-1799, is the assignee as recorded by the U.S. Patent Office at reel/frame 015075/0455 of an invention which is the subject of an application for Letters Patent of the United States ("Application") entitled "HUMAN ANTI-IFN- γ NEUTRALIZING ANTIBODIES AS SELECTIVE IFN- γ PATHWAY INHIBITORS," which is found in U.S. Application Serial No. 10/684,957, filed on October 14, 2003, which claims the benefit of U.S. Provisional Application No. 60/419,057 filed October 16, 2002 and U.S. Provisional Application No. 60/479,241 filed June 17, 2003.

Whereas MEDAREX, INC., a New Jersey corporation having its principal place of business at 707 State Road, Suite 206, Princeton, New Jersey 08540, wishes to acquire an undivided interest in all inventions disclosed in such Application:

Now, therefore, in consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, AMGEN INC., its successors and assigns (collectively "AMGEN") hereby sells, assigns, transfers and sets over unto MEDAREX, INC., its successors and assigns (collectively "MEDAREX") an undivided interest in, to and under the Application, and any provisional application(s) from which Application is derived, and all priority rights to which the Application may be entitled, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and of all other countries which may be granted for such inventions, or any of them, including divisional, continuation, and/or continuation-in-part applications based on the above-identified Application, all such inventions and all rights in such Application and Letters Patent to be held and enjoyed jointly by AMGEN and MEDAREX, each enjoying an equal, undivided interest.

AMGEN hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue any such Letters Patent which may be granted on the Application or any continuation or divisional applications based on the Application to AMGEN and MEDAREX as co-assignees of the entire right, title and interest therein and thereto.

In Witness Whereof I have executed this assignment on behalf of AMGEN on the 30th day of May, 2007.



Stuart L. Watt
Vice President, Law

UNITED STATES OF AMERICA

State of California)
)ss:
County of Ventura)


May 30 2007

Before me, a Notary Public for Ventura County, State of California, personally appeared

Stuart L. Watt

personally known to me - OR - proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Debra L. Merrill
Notary Public
My commission expires
May 30 2007